Trial Profile

A phase 1 trial of SYNT-101

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 22 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SYNT 101 (Primary)
Indications Obesity
Focus Adverse reactions; First in man

Most Recent Events

01 Jul 2025 According to a Syntis Bio media release, the company announced the close of a $33 million oversubscribed Series A financing. The funding also enables the advancement of lead program SYNT-101 through Phase 1 studies as a once-daily treatment for obesity.
10 Apr 2025 According to a Syntis Bio media release, the company plans to to submit an investigational new drug (IND) application to the U.S. FDA in H2 2025.
10 Apr 2025 Results published in the Syntis Bio Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com